Erbitux Phase III Study Meets Primary Endpoint

ImClone Systems and Bristol-Myers Squibb have reported results of a phase III study demonstrating that Erbitux plus Folfiri in untreated metastatic colorectal cancer has benefits over Folfiri alone.

More than 1000 patients were recruited from around the world to participate in the study, which was conducted by Merck KGaA, ImClone Systems’ Erbitux partner outside of North America.

Eric Rowinsky, chief medical officer and senior vice president of ImClone Systems, said: “Despite advancements, metastatic disease remains difficult to treat. This study demonstrates the potential benefit of adding Erbitux to first-line treatment of metastatic colorectal cancer.”